NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
13668-0594-87 | 13668-0594 | APREPITANT | APREPITANT | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oct. 21, 2020 | In Use | |||
55150-0366-10 | 55150-0366 | ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct. 15, 2021 | In Use | |
72205-0171-07 | 72205-0171 | ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb. 6, 2024 | In Use | |
72205-0172-07 | 72205-0172 | ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | 2.0 mg/2mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb. 6, 2024 | In Use | |
70121-1237-01 | 70121-1237 | AZACITIDINE | AZACITIDINE | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Feb. 9, 2022 | In Use | |
43598-0678-11 | 43598-0678 | AZACITIDINE | AZACITIDINE | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec. 13, 2017 | In Use | |
55150-0393-01 | 55150-0393 | AZACITIDINE | AZACITIDINE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan. 3, 2023 | In Use | |
00002-4483-54 | 00002-4483 | Abemaciclib | Verzenio | 50.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-5337-54 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Oct. 6, 2017 | In Use | |
00002-5337-63 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | March 5, 2020 | In Use |
Found 10,000 results in 4 milliseconds — Export these results